122 related articles for article (PubMed ID: 22546485)
1. Long-acting β2 agonists and corticosteroids restore the reduction of histone deacetylase activity and inhibit H2O2-induced mediator release from alveolar macrophages.
Perng DW; Su KC; Chou KT; Wu YC; Chen CS; Hsiao YH; Tseng CM; Chen YH; Hsueh TY; Lee YC
Pulm Pharmacol Ther; 2012 Aug; 25(4):312-8. PubMed ID: 22546485
[TBL] [Abstract][Full Text] [Related]
2. Corticosteroids and adrenoceptor agonists: the compliments for combination therapy in chronic airways diseases.
Sin DD; Man SF
Eur J Pharmacol; 2006 Mar; 533(1-3):28-35. PubMed ID: 16457807
[TBL] [Abstract][Full Text] [Related]
3. Effects of formoterol and salmeterol on cytokine release from monocyte-derived macrophages.
Donnelly LE; Tudhope SJ; Fenwick PS; Barnes PJ
Eur Respir J; 2010 Jul; 36(1):178-86. PubMed ID: 19926732
[TBL] [Abstract][Full Text] [Related]
4. Oxidative stress-induced glucocorticoid resistance is prevented by dual PDE3/PDE4 inhibition in human alveolar macrophages.
Milara J; Navarro A; Almudéver P; Lluch J; Morcillo EJ; Cortijo J
Clin Exp Allergy; 2011 Apr; 41(4):535-46. PubMed ID: 21395877
[TBL] [Abstract][Full Text] [Related]
5. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study.
Larsson K; Janson C; Lisspers K; Jørgensen L; Stratelis G; Telg G; Ställberg B; Johansson G
J Intern Med; 2013 Jun; 273(6):584-94. PubMed ID: 23495860
[TBL] [Abstract][Full Text] [Related]
6. Corticosteroid insensitivity is reversed by formoterol via phosphoinositide-3-kinase inhibition.
Rossios C; To Y; Osoata G; Ito M; Barnes PJ; Ito K
Br J Pharmacol; 2012 Oct; 167(4):775-86. PubMed ID: 22251095
[TBL] [Abstract][Full Text] [Related]
7. Effects of beta2-agonists and budesonide on interleukin-1beta and leukotriene B4 secretion: studies of human monocytes and alveolar macrophages.
Zetterlund A; Linden M; Larsson K
J Asthma; 1998; 35(7):565-73. PubMed ID: 9777883
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-10-secreting "regulatory" T cells induced by glucocorticoids and beta2-agonists.
Peek EJ; Richards DF; Faith A; Lavender P; Lee TH; Corrigan CJ; Hawrylowicz CM
Am J Respir Cell Mol Biol; 2005 Jul; 33(1):105-11. PubMed ID: 15845862
[TBL] [Abstract][Full Text] [Related]
9. Additive anti-inflammatory effects of beta 2 adrenoceptor agonists or glucocorticosteroid with roflumilast in human peripheral blood mononuclear cells.
Tannheimer SL; Sorensen EA; Haran AC; Mansfield CN; Wright CD; Salmon M
Pulm Pharmacol Ther; 2012 Apr; 25(2):178-84. PubMed ID: 22306235
[TBL] [Abstract][Full Text] [Related]
10. Combination of fluticasone propionate and salmeterol potentiates the suppression of cigarette smoke-induced IL-8 production by macrophages.
Sarir H; Mortaz E; Karimi K; Johnson M; Nijkamp FP; Folkerts G
Eur J Pharmacol; 2007 Sep; 571(1):55-61. PubMed ID: 17631879
[TBL] [Abstract][Full Text] [Related]
11. Corticosteroids plus long-acting β2-agonists prevent double-stranded RNA-induced upregulation of B7-H1 on airway epithelium.
Kan-O K; Matsumoto K; Inoue H; Fukuyama S; Asai Y; Watanabe W; Kurokawa M; Araya J; Kuwano K; Nakanishi Y
Int Arch Allergy Immunol; 2013; 160(1):27-36. PubMed ID: 22948082
[TBL] [Abstract][Full Text] [Related]
12. Switching from salmeterol/fluticasone to formoterol/budesonide combinations improves peripheral airway/alveolar inflammation in asthma.
Akamatsu T; Shirai T; Kato M; Yasui H; Hashimoto D; Fujisawa T; Tsuchiya T; Inui N; Suda T; Chida K
Pulm Pharmacol Ther; 2014 Feb; 27(1):52-6. PubMed ID: 23583566
[TBL] [Abstract][Full Text] [Related]
13. Differential control of TH1 versus TH2 cell responses by the combination of low-dose steroids with beta2-adrenergic agonists.
Goleva E; Dunlap A; Leung DY
J Allergy Clin Immunol; 2004 Jul; 114(1):183-91. PubMed ID: 15241363
[TBL] [Abstract][Full Text] [Related]
14. Oral Low-dose Theophylline on Top of Inhaled Fluticasone-Salmeterol Does Not Reduce Exacerbations in Patients With Severe COPD: A Pilot Clinical Trial.
Cosío BG; Shafiek H; Iglesias A; Yanez A; Córdova R; Palou A; Rodriguez-Roisin R; Peces-Barba G; Pascual S; Gea J; Sibila O; Barnes PJ; Agusti A
Chest; 2016 Jul; 150(1):123-30. PubMed ID: 27107490
[TBL] [Abstract][Full Text] [Related]
15. Formoterol and budesonide inhibit rhinovirus infection and cytokine production in primary cultures of human tracheal epithelial cells.
Yamaya M; Nishimura H; Nadine L; Kubo H; Nagatomi R
Respir Investig; 2014 Jul; 52(4):251-60. PubMed ID: 24998372
[TBL] [Abstract][Full Text] [Related]
16. Modulation of transcriptional responses by poly(I:C) and human rhinovirus: effect of long-acting β₂-adrenoceptor agonists.
Rider CF; Miller-Larsson A; Proud D; Giembycz MA; Newton R
Eur J Pharmacol; 2013 May; 708(1-3):60-7. PubMed ID: 23523474
[TBL] [Abstract][Full Text] [Related]
17. Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers.
Palmqvist M; Arvidsson P; Beckman O; Peterson S; Lötvall J
Pulm Pharmacol Ther; 2001; 14(1):29-34. PubMed ID: 11162416
[TBL] [Abstract][Full Text] [Related]
18. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.
Blais L; Forget A; Ramachandran S
Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effects of two long-acting beta2-agonists on cytokine secretion by human airway epithelial cells.
Chiu JC; Hsu JY; Fu LS; Chu JJ; Chi CS
J Microbiol Immunol Infect; 2007 Oct; 40(5):388-94. PubMed ID: 17932597
[TBL] [Abstract][Full Text] [Related]
20. Effect of budesonide and formoterol on IL-6 and IL-8 release from primary bronchial epithelial cells.
Strandberg K; Palmberg L; Larsson K
J Asthma; 2008 Apr; 45(3):201-3. PubMed ID: 18415826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
